Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy (Q76402661)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

title

Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Mayu O. Frank

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Robert B. Darnell

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

author name string

M Jegathesan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

N E Blachère

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

H I Scher

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

M L Albert

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

publication date

1 January 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

Prostate Cancer and Prostatic Diseases

24 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

page(s)

63-72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14999241%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500694

24 November 2019

exact match

0 references

cites work

Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Tumor-specific killer cells in paraneoplastic cerebellar degeneration.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Paraneoplastic neurological degenerations: keys to tumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Cell-Associated Ovalbumin Is Cross-Presented Much More Efficiently than Soluble Ovalbumin In Vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Early detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Prostate cancer diagnosis, staging and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Processing and presentation of antigens by dendritic cells: implications for vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Phagocyte recognition of apoptotic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Autologous dendritic cells for treatment of advanced cancer--an update.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Short-term kinetics of tumor antigen expression in response to vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

Ramifications of HLA class I polymorphism and population genetics for vaccine development.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500694

7 January 2021